Stoke Therapeutics, Inc. (STOK) — 8-K Filings

8-K Filings (15)

• Stoke Therapeutics Files 8-K — Dec 5, 2025 Risk: low
  Stoke Therapeutics, Inc. filed an 8-K on December 5, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, ot
• Stoke Therapeutics Files 8-K on Officer/Director Changes — Oct 6, 2025 Risk: low
  Stoke Therapeutics, Inc. filed an 8-K on October 6, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointmen
• Stoke Therapeutics Files 8-K — Aug 11, 2025 Risk: low
  On August 11, 2025, Stoke Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
• Stoke Therapeutics Files 8-K — Jul 10, 2025 Risk: low
  On July 10, 2025, Stoke Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No
• Stoke Therapeutics Files 8-K Report — Jun 4, 2025 Risk: low
  On June 4, 2025, Stoke Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Re
• Stoke Therapeutics Files 8-K with Material Agreement — Feb 18, 2025 Risk: medium
  On February 14, 2025, Stoke Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Other Events,
• Stoke Therapeutics Files 8-K Report — Jan 7, 2025 Risk: low
  On January 7, 2025, Stoke Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a
• Stoke Therapeutics Files 8-K Report — Dec 6, 2024 Risk: low
  On December 4, 2024, Stoke Therapeutics, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial stat
• Stoke Therapeutics Files 8-K — Sep 10, 2024 Risk: low
  On September 10, 2024, Stoke Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no speci
• Stoke Therapeutics Appoints New CMO, Adds Director — Jun 21, 2024 Risk: low
  Stoke Therapeutics, Inc. announced on June 18, 2024, the appointment of Dr. Barry L. Gelb as Chief Medical Officer and the election of Dr. Susan L. Robertson to
• Stoke Therapeutics Files 8-K on Shareholder Vote Matters — Jun 6, 2024 Risk: low
  Stoke Therapeutics, Inc. filed an 8-K on June 6, 2024, reporting on a submission of matters to a vote of security holders that occurred on June 5, 2024. The com
• Stoke Therapeutics Appoints New CMO, Director — Apr 29, 2024 Risk: low
  Stoke Therapeutics, Inc. announced on April 29, 2024, the appointment of Dr. Barry L. Gelb as Chief Medical Officer and the election of Dr. Sarah E. Michaels to
• Stoke Therapeutics Files 8-K Material Definitive Agreement — Mar 28, 2024 Risk: medium
  On March 27, 2024, Stoke Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such a
• Stoke Therapeutics Files 8-K — Mar 25, 2024 Risk: low
  Stoke Therapeutics, Inc. filed an 8-K on March 25, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
• Stoke Therapeutics Files 8-K, Confirms Nasdaq Listing — Jan 8, 2024
  Stoke Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded compan

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX